Who Should Not Use Ozempic for Weight Loss?

Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide medications like Ozempic have transformed weight loss treatment for millions, yet they're not appropriate for everyone. Specific medical histories, current conditions, and life circumstances require alternative approaches or careful clinical oversight before starting therapy.

Pregnancy and Breastfeeding: Why GLP-1 Medications Are Contraindicated

Semaglutide must be discontinued at least two months before attempting pregnancy because animal studies show potential fetal risks including skeletal and kidney abnormalities. Women who become pregnant while taking GLP-1 medications should contact their healthcare provider immediately to discuss stopping treatment safely.

Breastfeeding mothers should not use semaglutide, as it remains unknown whether the medication passes into breast milk or could affect an infant's development. This precaution applies throughout the entire nursing period, making pregnancy planning and contraception important discussions with your prescribing physician.

Personal or Family History of Medullary Thyroid Cancer

Patients with a personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) must never use GLP-1 agonists like semaglutide. Rodent studies demonstrated thyroid C-cell tumors at doses exceeding clinical exposure, creating an absolute contraindication that applies regardless of weight loss goals.

Family members with confirmed MEN 2 or MTC diagnosis face genetic screening requirements before semaglutide use. This inherited risk pattern means genetic counseling and thyroid baseline testing are prerequisites, and many physicians recommend avoiding the medication entirely for these populations to eliminate theoretical risk.

Severe Diabetic Retinopathy and Advanced Kidney Disease

Patients with severe diabetic retinopathy, particularly those with macular edema or recent eye procedures, require careful evaluation before starting semaglutide because rapid blood sugar reduction may temporarily worsen vision complications. The medication's mechanism of lowering glucose quickly can stress already-compromised retinal blood vessels.

Advanced chronic kidney disease (stages 4-5 with eGFR below 30 mL/min/1.73m²) presents challenges because semaglutide dosing data in this population remains limited, and gastrointestinal side effects could worsen dehydration in patients with reduced kidney function. Patients on dialysis should discuss alternatives with their nephrologist before starting GLP-1 therapy.

Pancreatitis History and Gallbladder Disease Considerations

Anyone with a personal history of acute or chronic pancreatitis should avoid semaglutide unless their gastroenterologist explicitly approves it, because GLP-1 medications alter pancreatic enzyme secretion and could theoretically trigger recurrence. Symptoms like severe abdominal pain warrant immediate medical evaluation to rule out pancreatitis.

Patients with active gallbladder disease or a history of gallstones face increased risk because semaglutide slows gastric emptying and alters bile flow, potentially triggering gallbladder complications. Those without a gallbladder typically tolerate semaglutide well, though individualized risk assessment remains important.

Why Personalized Genetic Testing Identifies Your Best Treatment Path

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

For patients with contraindications or concerns about standard semaglutide, genetic insights guide selection of Compounded Semaglutide Injection (starting at $189/mo (or $149/mo on the 6-month plan)) versus Microdose GLP-1 Protocol ($129/mo flat), Tirzepatide options, or the dual-compound GLP-Squared formulation. Licensed 503A compounding pharmacies allow dose customization that oral medications cannot provide, making precision testing especially valuable for high-risk or medically complex patients.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can I use semaglutide if I'm trying to get pregnant soon?

No. You must stop semaglutide at least two months before attempting pregnancy. If you're actively trying to conceive, discuss alternatives with your doctor now rather than starting GLP-1 therapy.

I have type 2 diabetes with severe eye problems from it. Can I still take Ozempic?

Severe diabetic retinopathy requires careful physician evaluation before starting any GLP-1 medication. Rapid blood sugar drops can temporarily worsen vision complications, so your endocrinologist or ophthalmologist must approve treatment and monitor closely.

What should I do if I have a family history of thyroid cancer?

Contact your doctor immediately before starting semaglutide. If you have a family member with medullary thyroid cancer or MEN 2 syndrome, genetic counseling is strongly recommended, and you may need to avoid GLP-1 medications entirely.

I had pancreatitis five years ago. Can I use semaglutide now?

Speak with a gastroenterologist before starting semaglutide if you have any history of pancreatitis. The medication alters pancreatic enzyme secretion and could increase recurrence risk, though individual medical history matters greatly.

How does PlexusDx Precision Peptide Genetic Testing help if I have medical concerns?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.